Cite
HARVARD Citation
Budde, P. et al. (n.d.). PS2:28 Autoantibody profiling in prostvac and ipilimumab treated prostate cancer patients reveals potential biomarkers of immune-related adverse events. Lupus science & medicine. pp. A45-A46. [Online].